Thompson Siegel & Walmsley’s Quest Diagnostics DGX Stock Holding History

Thompson Siegel & Walmsley’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.59M	Sell	26,355 -500	-2%	-$98.1K	0.1%	213
2026 Q1	$5.26M	Sell	26,855 -5,800	-18%	-$1.13M	0.09%	213
2025 Q4	$5.67M	Hold	32,655	–	–	0.1%	206
2025 Q3	$6.22M	Buy	+32,655	New	+$5.8M	0.1%	195
2024 Q1	–	Sell	-296	Closed	-$41K	–	403
2023 Q4	$41K	Sell	296 -20	-6%	-$2.63K	﹤0.01%	423
2023 Q3	$39K	Buy	316 +20	+7%	+$2.67K	﹤0.01%	428
2023 Q2	$42K	Hold	296	–	–	﹤0.01%	429
2023 Q1	$42K	Hold	296	–	–	﹤0.01%	431
2022 Q4	$46K	Buy	+296	New	+$42.5K	﹤0.01%	422
2022 Q1	–	Sell	-7	Closed	-$1K	–	645
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	622
2021 Q3	$1K	Hold	7	–	–	﹤0.01%	689
2021 Q2	$1K	Hold	7	–	–	﹤0.01%	714
2021 Q1	$1K	Buy	+7	New	+$863	﹤0.01%	695

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Thompson Siegel & Walmsley's DGX Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its Quest Diagnostics (DGX) stake by 1.9% in Q2 2026, selling an estimated $98.1K and leaving 26,355 shares worth $5.59M. The position accounts for 0.1% of the portfolio, ranked #213.

Thompson Siegel & Walmsley first reported a position in DGX in Q1 2021 and has held it in 13 quarters since. The position peaked at $6.22M in Q3 2025. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Thompson Siegel & Walmsley held 26,355 shares of Quest Diagnostics worth $5.59M as of Q2 2026.
Thompson Siegel & Walmsley sold 500 Quest Diagnostics shares in Q2 2026, an estimated $98.1K.
Quest Diagnostics made up 0.1% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #213 holding.
Thompson Siegel & Walmsley first reported a position in Quest Diagnostics in Q1 2021 and has held it in 13 quarters since.
Thompson Siegel & Walmsley's Quest Diagnostics position peaked at $6.22M in Q3 2025.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.